SCHEMBL21291599

SCHEMBL21291599

CN1CCN(C2(Cc3ccccc3)C=CC=C(N)C2N)CC1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.37
SIGMAR1 Q99720 1/20 0.34
HRH4 Q9H3N8 5/20 0.33
HTR6 P50406 2/20 0.33
HTR1A P08908 1/20 0.33
HTR2A P28223 1/20 0.33
HTR7 P34969 1/20 0.33
LMNA P02545 1/20 0.33
LTA4H P09960 1/20 0.33
GAA P10253 1/20 0.33
RAD52 P43351 1/20 0.33
KMT2A Q03164 1/20 0.33
IDO1 P14902 1/20 0.32
BCHE P06276 1/20 0.32
BACE1 P56817 1/20 0.32
OPRM1 P35372 1/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4968880 0.68 MAOA (0.34)
SCHEMBL14279644 0.65 GAA (0.55) MC4RSIGMAR1GAARAD52KMT2A
SCHEMBL3412905 0.62 GAA (0.46) MC4RSIGMAR1HRH4HTR6GAA
SCHEMBL8267929 0.61 MAOA (0.68) MC4RSIGMAR1GAARAD52KMT2A
SCHEMBL4124999 0.61 KMT2A (0.44) MC4RSIGMAR1GAARAD52KMT2A
SCHEMBL31389328 0.60 MC4R (0.50) MC4RSIGMAR1LMNAGAARAD52
SCHEMBL735929 0.60 KMT2A (0.43) MC4RSIGMAR1GAARAD52KMT2A
SCHEMBL4130873 0.60 CYP2D6 (0.43) MC4RSIGMAR1HTR2AGAARAD52
SCHEMBL14279640 0.59 SLC6A4 (0.56) SIGMAR1GAARAD52KMT2AOPRM1
SCHEMBL4168923 0.59 RAB9A (0.42) MC4RSIGMAR1HRH4LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2024-05-14 US disclosed
EP-3755688-B1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S A (PL) 2023-06-14 EP disclosed
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS ADAMED PHARMA S.A. (PL) 2021-09-09 US disclosed
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2021-06-15 US disclosed
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS ACADIA PHARMACEUTICALS INC. 2020-12-03 US disclosed
EP-3530651-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed sp. z o.o. (PL) 2019-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR2C, HTR6 MC4R 467/4885SIGMAR1 195/4885HRH4 260/4885
US-11034688-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C MC4R 521/4885SIGMAR1 229/4885HRH4 349/4885
US-20200377496-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A and 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C MC4R 521/4885SIGMAR1 229/4885HRH4 349/4885
US-20210276995-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR2C, HTR6 MC4R 467/4885SIGMAR1 195/4885HRH4 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.